Autoimmune Diseases
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global autoimmune disease drug development, market trends, and regulatory landscapes. Inform your pharma strategy.
Showing 1–2 of 2 articles
Quick answer
NovaPharmaNews Autoimmune Diseases hub for EMA covers 2 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
EULAR 2026: Immutep's IMP761 Phase I Data Preview
Roche's Gazyva Receives FDA Acceptance for Lupus Treatment Following Positive Phase III Trial Results
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.